Our Mission
Your Vision
Leading ophthalmology practice
in Sydney’s inner west.
Strathfield Retina Clinic is a leading ophthalmology practice located in Sydney’s inner west with retina specialists and surgeons highly trained in the diagnosis and treatment of disorders in the retina, vitreous, and macula in addition to general ophthalmology.
Strathfield Retina Clinic has an ongoing commitment to investing in cutting edge technology including the latest high resolution eye scanners, advanced laser surgery devices, therapeutic injections and surgical techniques. We are a tertiary referral centre where many patients with complex retinal conditions are referred for management.
Our Services
We treat the following conditions:
We are also an Eye Emergency Referral Centre and see urgent patients with symptoms of:
- Sudden or unexplained vision loss
- Acute red eye
- Flashes/ floaters or shadows
- Eye pain
- Eyelid lumps or lesions
- Eye trauma or injuries
Our Doctors
All nine doctors who practice at our clinic are members of ANZsRS (Australian and New Zealand society of Retina Specialists) and RANZCO (Royal Australian and New Zealand College of Ophthalmologists).
Dr James Wong
Dr Andrew Chang
Dr James Leong
Dr Charmaine Chung
Dr Son Huynh
Dr Rajeev Chalasani
Dr Elisa Cornish
Dr Amy Pai
Dr Hemal Mehta
Clinical Trials
Strathfield Retina Clinic has an ongoing commitment to clinical research and is an award-winning leading Clinical Trials Research site offering patients novel treatments for sight-threatening disorders.
Vabysmo (faricimab, Roche), has been listed on the Pharmaceutical Benefits Scheme (PBS) for the treatment of patients with macular oedema secondary to retinal vein occlusion (RVO).
Strathfield Retina Clinic is proud to have been involved in the pivotal multinational BALATON and COMINO Clinical Research trials of Vabysmo (faricimab) in RVO over the last several years. Our team of Retina Specialists, Clinical Orthoptists and Clinical Trial Coordinators have contributed as Principal Investigators and as a major site to this forefront research with a new therapeutic agent.
